Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-25-012186
Filing Date
2025-02-11
Accepted
2025-02-11 16:00:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 29400
  Complete submission text file 0001213900-25-012186.txt   31250
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Subject) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91228 | Film No.: 25609658
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

EIN.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A